In a Jan. 27 letter to Sen. Elizabeth Warren, Dr. Califf promised not to work or seek compensation from any drug or medical device companies for four years after his tenure if selected as commissioner. He also pledged to divest himself from business with which he had a previous working relationship for four years.
“I believe it is important to reassure the public at the outset that the previous positions will not bias or influence any of my decision-making on behalf of the agency,” Dr. Califf wrote in the letter.
Dr. Califf faces concerns about his previous role at Alphabet and investments in life science companies such as Walgreens Boots Alliance and Amgen, among others.
Ms. Warren’s spokesperson said she plans to support Dr. Califf’s nomination.
Read Dr. Califf’s letter here.
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
